Table 4.

Correlation of fatty acids with clinical and laboratory data in obese psoriatic patients (BMI ≥30)

Fatty acid	PASI	Disease duration	BMI	CRP	Cholest	TG	FBG	Vit D
Myristic (14:0)	−0.14	0.11	0.28	−0.04	0.34	0.71***	0.24	0.23
Palmitic (16:0)	0.07	−0.02	0.29	0.08	0.52*	0.81***	0.14	0.31
Palmitoleic (16:1n-7)	−0.11	−0.11	0.21	0.09	0.28	0.61**	0.28	0.01
Stearic (18:0)	0.16	−0.09	0.24	0.00	0.67***	0.56**	−0.01	0.31
Oleic (18:1n9c)	0.16	0.00	0.31	0.09	0.38	0.88***	0.07	0.11
Linoleic (18:2n-6)	0.04	−0.06	0.13	−0.17	0.71***	0.36	−0.28	0.37
Arachidic (20:0)	−0.09	−0.48*	−0.11	−0.04	0.52*	−0.18	0.01	−0.12
α-Linolenic (18:3n-3)	0.03	0.02	0.42*	−0.02	0.57**	0.71***	−0.00	0.11
Behenic (22:0)	−0.23	−0.14	0.01	−0.13	0.55**	−0.22	−0.05	0.10
Arachidonic (20:4n-6)	0.03	−0.40*	0.09	0.04	0.39	0.27	0.15	−0.05
Lignoceric (24:0)	−0.22	−0.14	−0.06	−0.23	0.59**	−0.31	−0.08	0.18
Eicozapentaenoic (20:5n-3)	−0.30	0.00	0.07	0.13	0.51*	−0.06	0.27	0.23
Nervonic (24:1n-9)	0.13	−0.31	−0.03	0.18	0.64**	−0.28	−0.01	0.17
Docozaheksaenoic (22:6n-3)	−0.17	−0.36	−0.01	0.07	0.52*	0.27	0.17	0.18
Total	0.02	0.06	0.32	0.06	0.66***	0.73***	0.09	0.35
n-3 PUFA	−0.21	−0.25	0.08	0.11	0.58**	0.30	0.19	0.18
n-6 PUFA	0.09	−0.14	0.15	−0.12	0.74***	0.42	−0.21	0.29
n-6/n-3 ratio	0.30	0.20	0.00	−0.15	−0.24	−0.06	−0.37	−0.05
%SFA	0.08	0.10	0.09	0.17	−0.23	0.47*	0.29	0.14
%MUFA	0.29	−0.16	0.11	0.26	−0.02	0.75***	0.27	−0.32
%PUFA	−0.05	−0.06	−0.04	−0.09	0.16	−0.62**	−0.34	0.03
SFA/UFA	0.02	0.16	0.08	0.13	−0.25	0.43*	0.31	0.19

Spearman’s R is shown

The significant correlations are marked as: * p < 0.05; ** p < 0.01; *** p < 0.001

PASI Psoriasis Area and Severity Index, BMI Body Mass Index, CRP C-reactive protein, Cholest cholesterol, TG triglycerides, FBG fasting blood glucose, Vit D vitamin D